Cormorant Asset Management’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Cormorant Asset Management’s Portfolio PRNB Stock Details PRNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,590,493	Closed	-$95.1M	–	99
2020 Q2	$95.1M	Sell	1,590,493 -509,507	-24%	-$31.5M	3.63%	5
2020 Q1	$125M	Buy	2,100,000 +109,078	+5%	+$6.36M	5.79%	3
2019 Q4	$109M	Buy	1,990,922 +649,026	+48%	+$24.2M	4.35%	5
2019 Q3	$37.9M	Sell	1,341,896 -20,002	-1%	-$734K	2.31%	12
2019 Q2	$45.2M	Sell	1,361,898 -50,000	-4%	-$1.56M	2.6%	13
2019 Q1	$48M	Sell	1,411,898 -62,464	-4%	-$1.99M	3.24%	9
2018 Q4	$40.4M	Sell	1,474,362 -12,536	-0.8%	-$323K	3.28%	8
2018 Q3	$43.4M	Buy	+1,486,898	New	+$42M	2.82%	12

Other funds holding PRNB

Ohio Public Employees Retirement System (OPERS) Columbus, Ohio $30.9B AUM 29.72% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADL

Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

Cormorant Asset Management's PRNB Position: Q3 2020 in Review

Cormorant Asset Management sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 1,590,493 shares — an estimated $95.1M sold.

Cormorant Asset Management first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $125M in Q1 2020. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

Cormorant Asset Management reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Cormorant Asset Management sold 1,590,493 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $95.1M.
Cormorant Asset Management first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
Cormorant Asset Management's Principia Biopharma Inc. Common Stock position peaked at $125M in Q1 2020.
9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on Cormorant Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.